Revenue breakdown: Product And Service (33.6%), Service Exemplar (23.5%), Service (23.5%).
8-K
Precigen, Inc. reported full year 2025 financial results, including $3.4 million in PAPZIMEOS net product revenue from its first partial quarter of U.S. commercial sales, total revenues up $5.8 million year-over-year, net loss attributable to common shareholders of $429.6 million or $1.37 per share, and cash, cash equivalents, and investments of $100.4 million as of December 31, 2025.